Effect of Dolutegravir coMpared to Darunavir/Cobicistat, both with Tenofovir Disoproxil Fumarate/Emtricitabine, On the severity of neuRopsychiatric efFects at 24 weeks of treatment in people living with HIV and baseline nEuropsychiatric disorders with no prior antiretrOviral therapy experience (MORFEO)
In a phase IV trial involving treatment-experienced men with baseline neuropsychiatric vulnerabilities, the DRV/c-based regimen demonstrated superior longitudinal stabilization of depressive symptoms, sleep, and daytime functioning with fewer treatment discontinuations compared to the DTG-based regimen, despite both achieving comparable virological suppression at 24 weeks.